- Home
- SLDB vs BALY Comparison
SLDB vs BALY Comparison
Compare SLDB & BALY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLDB | BALY |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | 11700 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.7M | 711.1M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SLDB | BALY |
|---|---|---|
| Price | $6.86 | $13.86 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 5 |
| Target Price | ★ $18.62 | $9.67 |
| AVG Volume (30 Days) | ★ 1.2M | 105.1K |
| Earning Date | 11-02-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.97 | 8.37 |
| EPS | ★ N/A | N/A |
| Revenue | $8,094,000.00 | ★ $2,436,189,000.00 |
| Revenue This Year | N/A | $19.05 |
| Revenue Next Year | N/A | $8.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.79 | $8.44 |
| 52 Week High | $11.45 | $20.74 |
Technical Indicators
Market Signals| Indicator | SLDB | BALY |
|---|---|---|
| Relative Strength Index (RSI) | 29.65 | 64.38 |
| Support Level | $6.76 | $12.59 |
| Resistance Level | $7.26 | $14.65 |
| Average True Range (ATR) | 0.39 | 0.83 |
| MACD | -0.06 | 0.09 |
| Stochastic Oscillator | 9.05 | 86.62 |
Price Performance
Historical ComparisonAbout SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
About BALY Bally's Corporation
Ballys Corp is a gaming, hospitality, entertainment, and technology company operating across casino, interactive, and lottery markets. It provides physical and interactive gaming experiences, including casino gaming, iGaming, sportsbook, online bingo, free-to-play games, and technology-driven lottery solutions. The company's segments include Casinos & Resorts, which generates maximum revenue and operates casino and resort properties, a horse racetrack, and a golf course; Bally's Intralot B2B, which provides lottery and technology services; Bally's Intralot B2C, which includes interactive gaming and lottery operations, including a UK casino; and North America Interactive, which includes sports betting and iGaming operations in the United States and Canada.